Results 191 to 200 of about 33,626 (230)
Identification of quinolinyl-containing dual soluble epoxide hydrolase/fatty acid amide hydrolase inhibitors with moderate potency towards acetylcholinesterase. [PDF]
Gonzalez M +5 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Drugs & Aging, 1997
Donepezil is a specific and potent acetylcholinesterase inhibitor according to in vitro data. It displays primarily noncompetitive inhibitory activity. In vivo, donepezil inhibited acetylcholinesterase activity in human erythrocytes and increased extracellular acetylcholine levels in the cerebral cortex and hippocampus of the rat.
H M, Bryson, P, Benfield
openaire +3 more sources
Donepezil is a specific and potent acetylcholinesterase inhibitor according to in vitro data. It displays primarily noncompetitive inhibitory activity. In vivo, donepezil inhibited acetylcholinesterase activity in human erythrocytes and increased extracellular acetylcholine levels in the cerebral cortex and hippocampus of the rat.
H M, Bryson, P, Benfield
openaire +3 more sources
Drugs of Today, 1998
Donepezil is a highly selective, long-acting acetylcholinesterase inhibitor which has been approved in numerous countries for the treatment of Alzheimer's disease. Donepezil increases the levels of acetylcholine in the brain of patients with Alzheimer's disease and presumably corrects some dysfunction associated with loss of cells in the basal ...
+5 more sources
Donepezil is a highly selective, long-acting acetylcholinesterase inhibitor which has been approved in numerous countries for the treatment of Alzheimer's disease. Donepezil increases the levels of acetylcholine in the brain of patients with Alzheimer's disease and presumably corrects some dysfunction associated with loss of cells in the basal ...
+5 more sources
Drugs & Aging, 2003
Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer's disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in VaD.
David R, Goldsmith, Lesley J, Scott
openaire +2 more sources
Vascular dementia (VaD), caused by stroke or small vessel disease, is the second most common form of dementia after Alzheimer's disease (AD). Donepezil, an acetylcholinesterase inhibitor currently indicated for use in patients with mild to moderate AD, has recently been evaluated in VaD.
David R, Goldsmith, Lesley J, Scott
openaire +2 more sources

